Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Autolus Therapeutics plc

< Previous 1 2 Next >
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces participation in upcoming conferences
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces publication in Cancer Immunology Research
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL CAH
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Host Virtual Capital Markets Day
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Publication in Molecular Therapy
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces resignation of Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback